Revance Securities Settlement
Not yet determinable; depends on number of valid claims submitted
Last verified July 12, 2026Source: claimdepotHow ClaimWatch verifies cases
This settlement is closed to new claims — the deadline was August 28, 2026. You can still see what it was about and follow the case in court below. Looking for money you can still claim? Browse open settlements →
What happened
Revance Therapeutics and its executives made material misrepresentations and omissions regarding the company's relationship with Teoxane SA and the tender offer and merger transaction with Crown Laboratories, Inc., allegedly violating federal securities laws. Defendants deny any wrongdoing or liability.
Do you qualify?
Anyone who purchased or acquired Revance Therapeutics common stock (ticker "RVNC") or 1.75% fixed coupon Convertible Senior Unsecured Notes between February 29, 2024 through the close of the merger on February 6, 2025, inclusive.
How to file
File a Proof of Claim and Release Form by August 28, 2026, either by mail (postmarked by deadline) or online. You must provide documentation of your purchase or acquisition of Revance securities.
Common questions
- How much does the Revance Securities Settlement pay?
- Estimated payout: Not yet determinable; depends on number of valid claims submitted. The total settlement fund is $17M. Actual amounts depend on how many valid claims are filed — most settlements divide a fixed fund pro rata, so a higher claim rate means a smaller individual check. An "up to" figure is a cap, not a guarantee.
- What is the claim deadline for the Revance Securities Settlement?
- This settlement is closed to new claims — the deadline was August 28, 2026. Once a claim deadline passes you generally forfeit your share, even if you qualified.
- Do I need proof of purchase for the Revance Securities Settlement?
- Yes. This settlement asks for documentation supporting your claim — a receipt, an account record, or the notice you were sent. Check the official settlement website for exactly which documents are accepted.
- Is the Revance Securities Settlement notice real, or a scam?
- Claims are filed at revancesecuritiessettlement.com. Filing a class action claim is always free — no legitimate settlement charges you to claim, and no administrator will ask for payment, a gift card, or your full Social Security number by email or text. If a notice asks for any of those, it is not from the administrator. When in doubt, ignore the link you were sent and go to the official settlement website directly.
- When will payments from the Revance Securities Settlement be sent?
- Class action payouts typically take 12 to 24 months after the claim deadline, and longer if the settlement is appealed. The final approval hearing for this case is set for August 10, 2026; no payments can be issued before a settlement receives final approval.
Who's involved
Plaintiffs
- Chicago Capital Management, LP
- iMGP Alternative Strategies Fund
- AltShares Event-Driven ETF
- AltShares Merger Arbitrage ETF
- The Arbitrage Fund
- Aabash Pokhrel
- Cassandra Matney
Defendants
- Tobin C. Schilke
- Mark J. Foley
- Revance Therapeutics, Inc.
Counsel for plaintiffs
- Vincent R. CappucciEntwistle & Cappucci LLP
- Robert N. CappucciEntwistle & Cappucci LLP
- Callie CrispinEntwistle & Cappucci LLP
- Brendan J. BrodeurEntwistle & Cappucci LLP
- Andrew J. EntwistleEntwistle & Cappucci LLP
- James Gerard Stranch , IVStranch, Jennings & Garvey, PLLC
- James A. Holifield , Jr.Holifield & Janich PLLC
- Joseph Dylan HarperHoltzman Vogel
- Robert P. BramlettBramlett Law Offices
- Paul Kent BramlettBramlett Law Offices
- Joshua E. FruchterWohl & Fruchter LLP
- Jeremy A. LiebermanPomerantz LLP (NY Office)
- J. Alexander Hood , IIPomerantz LLP (NY Office)
Counsel for defendants
- Susan L. SaltzsteinSkadden, Arps, Slate, Meagher & Flom LLP (New York)
- Milton S. McGee , IIIRiley & Jacobson, PLC
- Jordan D. PetersonKirkland & Ellis (NY)
- Jenness E. ParkerSkadden, Arps, Slate, Meagher & Flom, LLP
- Jeffrey S. GeierSkadden, Arps, Slate, Meagher & Flom LLP (New York)
- Christopher E. ThorsenBaker, Donelson, Bearman, Caldwell & Berkowitz, PC (Nash)
- Christopher R. FredmonskiSkadden, Arps, Slate, Meagher & Flom LLP (New York)
Parties and counsel from the public court docket. Listing an attorney here isn't an endorsement, and ClaimWatch isn't affiliated with any of them.
In the news
- Revance Therapeutics, Inc. (NASDAQ:RVNC) Shares Sold by Jane Street Group LLCETF Daily News · June 2, 2025
- Millennium Management LLC Increases Position in Revance Therapeutics, Inc. (NASDAQ:RVNC)ETF Daily News · May 29, 2025
- Revance Therapeutics (NASDAQ:RVNC) Now Covered by StockNews.comETF Daily News · May 21, 2025
- Revance Therapeutics (NASDAQ:RVNC) Coverage Initiated by Analysts at StockNews.comETF Daily News · May 15, 2025
Headlines via NewsAPI. ClaimWatch isn't affiliated with these publications.
New to class actions?
This summary was generated from public settlement documents and may contain errors. Confirm eligibility, deadlines, and payment terms on the official settlement website before filing. ClaimWatch is not a law firm and this is not legal advice. Filing a claim is free.
More securities settlements
View all →Eagle Pharma Securities Litigation Settlement
Eagle Pharmaceuticals, Inc. is the subject of a securities litigation class action. Shareholders who purchased the company's publicly traded common stock between August 9, 2022 and October 1, 2024 allege claims covered by this settlement, which the defendant has agreed to settle.
…moreHut 8 Corp. Securities Class Action Settlement
Hut 8 Corp. and individual defendants are accused of alleged securities violations. The company and defendants have agreed to settle claims from investors who purchased securities during the class period without admitting wrongdoing.
Kornit Digital Ltd. Securities Litigation Settlement
Kornit Digital Ltd. and its executives are accused of securities fraud in this class action lawsuit. The defendants have denied all claims and admit no wrongdoing, but have agreed to settle the case for $19.5 million to eliminate the burden and expense of continued litigation.
…more